Is United Therapeutics Stock a Good Investment?
United Therapeutics Investment Advice | UTHR |
- Examine United Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research United Therapeutics' leadership team and their track record. Good management can help United Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact United Therapeutics' business and its evolving consumer preferences.
- Compare United Therapeutics' performance and market position to its competitors. Analyze how United Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if United Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about United Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in United Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if United Therapeutics is a good investment.
Sell | Buy |
Strong Buy
Market Performance | Good | Details | |
Volatility | Very steady | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Moves slightly opposite to the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine United Therapeutics Stock
Researching United Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 98.0% of the company outstanding shares are owned by institutional investors. The company has Price to Book (P/B) ratio of 1.83. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. United Therapeutics recorded earning per share (EPS) of 19.8. The entity had not issued any dividends in recent years. The firm had 2:1 split on the 23rd of September 2009.
To determine if United Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding United Therapeutics' research are outlined below:
| United Therapeutics is unlikely to experience financial distress in the next 2 years | |
| Over 98.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from investing.com: Top Value Stocks deliver 5.70 percent YTD return, outpacing benchmarks ProPicks Report |
United Therapeutics Quarterly Cost Of Revenue |
|
United Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in United Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to United Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 28th of February 2024 Upcoming Quarterly Report | View | |
| 1st of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 28th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact United Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises United Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2003-11-06 | 2003-09-30 | -0.04 | -0.03 | 0.01 | 25 | ||
2005-05-03 | 2005-03-31 | 0.14 | 0.16 | 0.02 | 14 | ||
2003-05-06 | 2003-03-31 | -0.09 | -0.07 | 0.02 | 22 | ||
2003-02-25 | 2002-12-31 | -0.08 | -0.06 | 0.02 | 25 | ||
2002-11-08 | 2002-09-30 | -0.16 | -0.14 | 0.02 | 12 | ||
2010-04-29 | 2010-03-31 | 0.29 | 0.32 | 0.03 | 10 | ||
2008-05-01 | 2008-03-31 | 0.27 | 0.24 | -0.03 | 11 | ||
2004-05-06 | 2004-03-31 | -0.01 | -0.04 | -0.03 | 300 |
Know United Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as United Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading United Therapeutics backward and forwards among themselves. United Therapeutics' institutional investor refers to the entity that pools money to purchase United Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Aqr Capital Management Llc | 2023-12-31 | 551.8 K | Nuveen Asset Management, Llc | 2023-12-31 | 491.5 K | Farallon Capital Management, L.l.c. | 2023-12-31 | 476 K | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 459.7 K | Norges Bank | 2023-12-31 | 457.1 K | Fuller & Thaler Asset Management Inc | 2023-12-31 | 431.1 K | Palo Alto Investors, Llc | 2023-12-31 | 395.8 K | Orbimed Advisors, Llc | 2023-12-31 | 386.1 K | Lsv Asset Management | 2023-12-31 | 377.4 K | Blackrock Inc | 2023-12-31 | 5.3 M | Vanguard Group Inc | 2023-12-31 | 4.7 M |
United Therapeutics' market capitalization trends
The company currently falls under 'Large-Cap' category with a current market capitalization of 11.45 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate United Therapeutics's market, we take the total number of its shares issued and multiply it by United Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Market Cap |
|
United Therapeutics' profitablity analysis
United Therapeutics' profitability indicators refer to fundamental financial ratios that showcase United Therapeutics' ability to generate income relative to its revenue or operating costs. If, let's say, United Therapeutics is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, United Therapeutics' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of United Therapeutics' profitability requires more research than a typical breakdown of United Therapeutics' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.14 | 0.15 | |
| Return On Capital Employed | 0.19 | 0.20 | |
| Return On Assets | 0.14 | 0.14 | |
| Return On Equity | 0.16 | 0.17 |
Determining United Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if United Therapeutics is a good buy. For example, gross profit margin measures United Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of United Therapeutics' profitability and make more informed investment decisions.
The data published in United Therapeutics' official financial statements usually reflect United Therapeutics' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of United Therapeutics. For example, before you start analyzing numbers published by United accountants, it's critical to develop an understanding of what United Therapeutics' liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of United Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, United Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in United Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of United Therapeutics. Please utilize our Beneish M Score to check the likelihood of United Therapeutics' management manipulating its earnings.
Evaluate United Therapeutics' management efficiency
United Therapeutics has return on total asset (ROA) of 0.1122 % which means that it generated a profit of $0.1122 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1827 %, meaning that it created $0.1827 on every $100 dollars invested by stockholders. United Therapeutics' management efficiency ratios could be used to measure how well United Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of 05/03/2024, Return On Tangible Assets is likely to grow to 0.15. Also, Return On Capital Employed is likely to grow to 0.20. At this time, United Therapeutics' Return On Tangible Assets are relatively stable compared to the past year. As of 05/03/2024, Debt To Assets is likely to grow to 0.10, while Other Assets are likely to drop slightly above 284.7 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 127.88 | 134.27 | |
| Net Current Asset Value | 0.00 | 0.00 | |
| Tangible Asset Value | 0.00 | 0.00 | |
| Tangible Book Value Per Share | 125.44 | 131.71 | |
| Enterprise Value Over EBITDA | 7.05 | 6.70 | |
| Price Book Value Ratio | 1.72 | 1.63 | |
| Enterprise Value Multiple | 7.05 | 6.70 | |
| Price Fair Value | 1.72 | 1.63 | |
| Enterprise Value | 11.2 B | 11.8 B |
The analysis of United Therapeutics' management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze United Therapeutics' future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of United Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Beta 0.55 |
Basic technical analysis of United Stock
As of the 3rd of May, United Therapeutics has the Semi Deviation of 1.3, risk adjusted performance of 0.1068, and Coefficient Of Variation of 642.03. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of United Therapeutics, as well as the relationship between them. In other words, you can use this information to find out if the company will indeed mirror its model of past prices and volume data, or the prices will eventually revert. We have analyze and collected data for nineteen technical drivers for United Therapeutics, which can be compared to its competition. Please validate United Therapeutics coefficient of variation, maximum drawdown, as well as the relationship between the Maximum Drawdown and skewness to decide if United Therapeutics is priced more or less accurately, providing market reflects its prevalent price of 262.4 per share. Given that United Therapeutics has jensen alpha of 0.2728, we advise you to double-check United Therapeutics's current market performance to make sure the company can sustain itself at a future point.United Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific United Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on United Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases United Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Understand United Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing United Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.1068 | |||
| Market Risk Adjusted Performance | 1.1 | |||
| Mean Deviation | 1.3 | |||
| Semi Deviation | 1.3 | |||
| Downside Deviation | 1.64 | |||
| Coefficient Of Variation | 642.03 | |||
| Standard Deviation | 1.89 | |||
| Variance | 3.58 | |||
| Information Ratio | 0.1266 | |||
| Jensen Alpha | 0.2728 | |||
| Total Risk Alpha | 0.1518 | |||
| Sortino Ratio | 0.1461 | |||
| Treynor Ratio | 1.09 | |||
| Maximum Drawdown | 9.9 | |||
| Value At Risk | (1.95) | |||
| Potential Upside | 2.78 | |||
| Downside Variance | 2.69 | |||
| Semi Variance | 1.7 | |||
| Expected Short fall | (1.39) | |||
| Skewness | 1.16 | |||
| Kurtosis | 6.5 |
| Risk Adjusted Performance | 0.1068 | |||
| Market Risk Adjusted Performance | 1.1 | |||
| Mean Deviation | 1.3 | |||
| Semi Deviation | 1.3 | |||
| Downside Deviation | 1.64 | |||
| Coefficient Of Variation | 642.03 | |||
| Standard Deviation | 1.89 | |||
| Variance | 3.58 | |||
| Information Ratio | 0.1266 | |||
| Jensen Alpha | 0.2728 | |||
| Total Risk Alpha | 0.1518 | |||
| Sortino Ratio | 0.1461 | |||
| Treynor Ratio | 1.09 | |||
| Maximum Drawdown | 9.9 | |||
| Value At Risk | (1.95) | |||
| Potential Upside | 2.78 | |||
| Downside Variance | 2.69 | |||
| Semi Variance | 1.7 | |||
| Expected Short fall | (1.39) | |||
| Skewness | 1.16 | |||
| Kurtosis | 6.5 |
Consider United Therapeutics' intraday indicators
United Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of United Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
United Therapeutics Corporate Filings
F4 | 3rd of May 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10Q | 1st of May 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
| 29th of April 2024 Other Reports | ViewVerify |
United Stock media impact
Far too much social signal, news, headlines, and media speculation about United Therapeutics that are available to investors today. That information is available publicly through United media outlets and privately through word of mouth or via United internal channels. However, regardless of the origin, that massive amount of United data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of United Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of United Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to United Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive United Therapeutics alpha.
United Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards United Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
United Therapeutics Historical Investor Sentiment
Investor biases related to United Therapeutics' public news can be used to forecast risks associated with an investment in United. The trend in average sentiment can be used to explain how an investor holding United can time the market purely based on public headlines and social activities around United Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
United Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for United Therapeutics and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average United Therapeutics news discussions. The higher the estimate score, the more favorable the investor's outlook on United Therapeutics.
United Therapeutics Maximum Pain Price across 2024-05-17 Option Contracts
United Therapeutics' options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of United Therapeutics close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of United Therapeutics' options.
Be your own money manager
Our tools can tell you how much better you can do entering a position in United Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Content Syndication Now
Content SyndicationQuickly integrate customizable finance content to your own investment portal |
| All Next | Launch Module |
United Therapeutics Corporate Directors
United Therapeutics corporate directors refer to members of an United Therapeutics board of directors. The board of directors generally takes responsibility for the United Therapeutics' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of United Therapeutics' board members must vote for the resolution. The United Therapeutics board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| Christopher Causey | Independent Director | Profile | |
| Richard Giltner | Independent Director | Profile | |
| Katherine Klein | Director | Profile | |
| Raymond Dwek | Non-Independent Director | Profile |
How to buy United Stock?
To provide specific investment advice or recommendations on United Therapeutics stock, we recommend investors consider the following general factors when evaluating United Therapeutics. This will help you to make an informed decision on whether to include United Therapeutics in one of your diversified portfolios:- Examine United Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research United Therapeutics' leadership team and their track record. Good management can help United Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact United Therapeutics' business and its evolving consumer preferences.
- Compare United Therapeutics' performance and market position to its competitors. Analyze how United Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if United Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about United Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in United Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if United Therapeutics is a good investment.
Already Invested in United Therapeutics?
The danger of trading United Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of United Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than United Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile United Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether United Therapeutics is a strong investment it is important to analyze United Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact United Therapeutics' future performance. For an informed investment choice regarding United Stock, refer to the following important reports: Check out World Market Map to better understand how to build diversified portfolios, which includes a position in United Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate. To learn how to invest in United Stock, please use our How to Invest in United Therapeutics guide.Note that the United Therapeutics information on this page should be used as a complementary analysis to other United Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Complementary Tools for United Stock analysis
When running United Therapeutics' price analysis, check to measure United Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy United Therapeutics is operating at the current time. Most of United Therapeutics' value examination focuses on studying past and present price action to predict the probability of United Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move United Therapeutics' price. Additionally, you may evaluate how the addition of United Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |
Is United Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of United Therapeutics. If investors know United will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about United Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.626 | Earnings Share 19.8 | Revenue Per Share 49.733 | Quarterly Revenue Growth 0.251 | Return On Assets 0.1122 |
The market value of United Therapeutics is measured differently than its book value, which is the value of United that is recorded on the company's balance sheet. Investors also form their own opinion of United Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is United Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because United Therapeutics' market value can be influenced by many factors that don't directly affect United Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between United Therapeutics' value and its price, as these two are different measures arrived at by various means. Investors typically determine if United Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, United Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.